Proactive Investors - Run By Investors For Investors

Shield Therapeutics to continue “robust” defence of IP as Teva appeals Feraccru ruling

The pharmaceutical firm said no date for the appeal hearing had yet been set but it believed the initial EPO decision in its favour would be upheld
Teva is appealing an initial EPO decision in favour of Shield in March

Shield Therapeutics PLC (LON:STX) has said it will continue to “robustly defend” its intellectual property (IP) after receiving notice that Teva Pharmaceutical Industries Ltd had appealed a ruling by the European Patent Office (EPO) regarding STX’s Feraccru iron deficiency treatment.

The news followed an EPO decision in March when it found in favour of Shield in relation to patent #2 668 175, which covers a "Process for preparing an iron hydroxypyrone".

WATCH: Shield Therapeutics accelerating commercial plans ahead of FDA decision

Shield said no date for the appeal hearing had yet been set but it believed the initial EPO decision would be upheld and would update on proceedings as required.

In a note, analysts at Shield’s ‘house’ broker Peel Hunt said appeals of this kind were “typical” of the generics industry and the original decision and breadth of the Feraccru patent provided significant defensibility for the company’s IP.

In early trading on Monday, Shield shares were 7% lower at 106p.

--Adds share price--

View full STX profile View Profile

Shield Therapeutics PLC Timeline

Related Articles

February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use